Zydus Lifesciences shares rise on final USFDA approval for Bosentan tablets

Zydus Lifesciences

Shares of Zydus Lifesciences shares rose in the opening trade on February 19 after the company received final approval from the United States Food and Drug Administration (USFDA) for Bosentan tablets for oral suspension, 32 mg.

At 09:18am Zydus Lifesciences was quoting at Rs 915.75, up Rs 5.70, or 0.63 percent, on the BSE.

Bosentan tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension (PAH), particularly to improve exercise ability and reduce clinical worsening in children aged three years and older with idiopathic or congenital PAH.

The drug is a dual endothelin receptor antagonist that helps lower high blood pressure in the lungs and is generally administered based on body weight, company said.

The approved product will be manufactured at the group’s formulation manufacturing facility located at SEZ, Ahmedabad, it added.

With this latest approval, the group now has 432 approvals and has filed 505 ANDAs since it began the filing process in FY 2003-04.

Catch all the market action on our live blog

February 17: The company launched PEPAIR™, India’s first affordable Oscillating Positive Expiratory Pressure (OPEP) device featuring a 3-resistance system. The device is designed to help clear congestion, support effective mucus clearance, and improve breathing in patients suffering from COPD, asthma, and bronchiectasis.

February 14: The company also received final approval from the US Food and Drug Administration (USFDA) for Ammonium Lactate Cream, 12%, which is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris, an inherited skin condition causing excessive dryness and scaling.

In the previous trading session, shares of Zydus Lifesciences closed at ₹910.05, rising ₹3.30, or 0.36 percent.

The stock had touched a 52-week high of ₹1,059.00 on September 19, 2025, and a 52-week low of ₹797.05 on April 7, 2025. At the current price, the stock is trading 14.07 percent below its 52-week high and 14.18 percent above its 52-week low.

The company’s market capitalisation stands at ₹91,572.32 crore.

The company had reported 1.8 percent rise in its December quarter net profit to Rs 1042.1 crore, while revenue from operations surged 30 percent YoY to Rs 6864.5 crore.